Literature DB >> 32314225

Bempedoic Acid: First Approval.

Anthony Markham1.   

Abstract

Bempedoic acid is a non-statin antihyperlipidaemic drug being developed by Esperion Therapeutics for the treatment of hypercholesterolaemia. Based on positive findings in the phase III CLEAR clinical trial programme, bempedoic acid has been approved in the USA and in the EU as monotherapy (NEXLETOL® in the USA, Nilemdo® in the EU) and as a fixed-dose combination with ezetimibe (NEXLIZET® in the USA, Nustendi® in the EU). This article summarizes the milestones in the development of bempedoic acid leading to these first approvals.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32314225     DOI： 10.1007/s40265-020-01308-w

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  1 in total

Review 1.  A Review of the Efficacy and Tolerability of Bempedoic Acid in the Treatment of Hypercholesterolemia.

Authors:  Stephanie Niman; Khyatiben Rana; Jessica Reid; Mae Sheikh-Ali; Todd Lewis; Rushab R Choksi; Rebecca F Goldfaden
Journal:  Am J Cardiovasc Drugs       Date:  2020-03-13       Impact factor: 3.571
  1 in total
  7 in total

Review 1.  Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics.

Authors:  Yajun Duan; Ke Gong; Suowen Xu; Feng Zhang; Xianshe Meng; Jihong Han
Journal:  Signal Transduct Target Ther       Date:  2022-08-02

Review 2.  Bempedoic Acid: The New Kid on the Block for the Treatment of Dyslipidemia and LDL Cholesterol: A Narrative Review.

Authors:  Uazman Alam; Dalal Y Al-Bazz; Handrean Soran
Journal:  Diabetes Ther       Date:  2021-05-26       Impact factor: 2.945

Review 3.  Engineering Cardiovascular Tissue Chips for Disease Modeling and Drug Screening Applications.

Authors:  Alex H P Chan; Ngan F Huang
Journal:  Front Bioeng Biotechnol       Date:  2021-04-20

Review 4.  Lipogenesis inhibitors: therapeutic opportunities and challenges.

Authors:  Battsetseg Batchuluun; Stephen L Pinkosky; Gregory R Steinberg
Journal:  Nat Rev Drug Discov       Date:  2022-01-14       Impact factor: 112.288

5.  A Nutrient-Based Cellular Model to Characterize Acetylation-Dependent Protein-Protein Interactions.

Authors:  Jérémy Loehr; Pata-Eting Kougnassoukou Tchara; Kevin Gonthier; Chahinez Noufi; Naomie Linteau; Étienne Audet-Walsh; Jean-Philippe Lambert
Journal:  Front Mol Biosci       Date:  2022-03-23

Review 6.  Advancements in the Treatment of Homozygous Familial Hypercholesterolemia.

Authors:  Archna Bajaj; Marina Cuchel
Journal:  J Atheroscler Thromb       Date:  2022-04-24       Impact factor: 4.394

Review 7.  Newer and Emerging LDL-C Lowering Agents and Implications for ASCVD Residual Risk.

Authors:  Rishi Rikhi; Michael D Shapiro
Journal:  J Clin Med       Date:  2022-08-08       Impact factor: 4.964
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.